Search
Displaying 1 result
Rilzabrutinib
go.drugbank.com/drugs/DB17709
ApprovedInvestigational
Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune thrombocytopenia (ITP). ITP is an autoimmune disorder characterized by low platelet count. Rilzabrutinib is thought to work by dual ...